BCMA CAR-T

BIOLOGICAL6 trials

Sponsors

Henan Cancer Hospital, Hebei Senlang Biotechnology Inc., Ltd., Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple MyelomaMultiple Myeloma, Newly DiagnosedMultiple Myeloma, Plasma Cell LeukemiaRelapsed or Refractory Multiple Myeloma

Early Phase 1

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2020-04-01End: 2023-03-30Target: 50Updated: 2020-11-13

Phase 1

Study of BCMA CAR-T in Multiple Myeloma

Henan Cancer HospitalMultiple Myeloma

Start: 2017-12-08End: 2019-12-31Target: 10Updated: 2017-12-29

Phase 2

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

RecruitingNCT07106736

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma, Newly Diagnosed

Start: 2025-08-10End: 2029-08-01Target: 60Updated: 2025-08-06

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

RecruitingNCT07106684

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma, Plasma Cell Leukemia

Start: 2025-08-10End: 2029-08-01Target: 20Updated: 2025-08-06

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

RecruitingNCT07106710

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma, Newly Diagnosed

Start: 2025-08-10End: 2028-08-01Target: 30Updated: 2025-08-06

Unknown Phase

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.Multiple Myeloma

Start: 2020-06-30End: 2022-12-30Target: 20Updated: 2020-09-29

Related Papers

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma

Blood Advances2025-06-262 citations

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Blood2023-11-022 citations